Zeiping Gui, People's Republic of China

Zeping Gui, M.D., is a physician-scientist trained jointly at Nanjing Medical University and Harvard Medical School. He is currently an Associate Professor at Nanjing Medical University and a Postdoctoral Research Fellow at the Thomas E. Starzl Transplantation Institute, University of Pittsburgh. He holds a U.S. medical license and was selected by the China Scholarship Council as a high-level visiting scholar. He is a member of the American Society of Transplantation, the American Society of Nephrology, and the American Medical Association. Dr. Gui has authored over 20 SCI papers with a cumulative impact factor exceeding 150. He has led research projects funded by the American Society of Nephrology ($150,000), the American Transplant Congress ($100,000), and the Jiangsu Provincial University Innovation Program (¥50,000). He has also contributed to NIH R01 grants, the National Natural Science Foundation of China, and provincial talent development programs including the "333 High-level Talent Project" and the "Six Talent Peaks" plan. His research focuses on immune mechanisms and individualized treatment strategies for chronic allograft injury. Using multi-omics analysis, single-cell sequencing, and mouse transplant models, he uncovered the role of M1 macrophages, B-cell differentiation, and Th17 polarization in antibody-mediated rejection (ABMR) and fibrosis progression. He also developed novel RNA and metabolic markers for monitoring immune injury and designed precision interventions based on immunogenetic and pharmacogenomic profiling. His translational work in developing gene-based diagnostic kits and optimizing immunosuppressive regimens has been clinically applied in kidney transplant centers, improving long-term graft outcomes. His findings have been published in top-tier journals (JCI, Advanced Science, Transplantation, Clinical and Translational Medicine) and presented at major transplant congresses worldwide.